Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

Fredrik Schjesvold,Bruno Paiva,Vincent Ribrag,Paula Rodriguez-Otero, Jesus F. San-Miguel,Pawel Robak,Markus Hansson,Maika Onishi,Habib Hamidi,Vikram Malhi,Monique Dail, Apurva Javery,Grace Ku,Marc S. Raab

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 2|浏览7

暂无评分

摘要

•Cobi, cobi-ven and cobi-ven-atezo were safe and tolerable in patients with R/R MM.•Cobi-ven and cobi-ven-atezo had moderate activity in all-comers.•Cobi-ven and cobi-ven-atezo had higher activity in patients with t(11;14)+ MM.

查看译文

关键词

Mitogen-activated protein kinase pathway, Immunotherapy,B-cell lymphoma-2, Programmed death-ligand 1,Biomarker

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要